Drug Profile


Alternative Names: Lu 31-130; LU 31130

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Antipsychotics
  • Mechanism of Action Neurotransmitter receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 09 Jun 2015 No recent reports on development identified - Phase-II for Schizophrenia in USA, Germany, Hong Kong, Indonesia, Philippines, Spain and Thailand (PO)
  • 09 Jun 2015 No recent reports on development identified - Phase-III for Schizophrenia in Czech Republic, Estonia, Finland, France and Poland (PO)
  • 11 Apr 2012 Lundbeck completes enrolment in its phase III trial for Schizophrenia in the Czech Republic, Estonia, Finland, France, and Poland (NCT01295372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top